In search of therapeutic agents capable of reversing the progression of MS, we discovered that IndCl, a novel highly selective ERβ ligand, reduces CNS inflammation, promotes remyelination, and ameliorates disease in the EAE and cuprizone models of MS10. Here, ESR2 is linked to myeloid sarcoma.